Share on StockTwits

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) have received an average rating of “Hold” from the fifteen brokerages that are covering the company, AR Network reports. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $26.92.

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 17.64 on Wednesday. Auxilium Pharmaceuticals has a 1-year low of $16.36 and a 1-year high of $32.89. The stock’s 50-day moving average is $19. and its 200-day moving average is $23.8. The company’s market cap is $886.5 million. Auxilium Pharmaceuticals also was the target of a large decline in short interest in July. As of July 31st, there was short interest totalling 12,858,783 shares, a decline of 6.9% from the July 15th total of 13,809,803 shares. Based on an average trading volume of 968,566 shares, the days-to-cover ratio is presently 13.3 days. Approximately 25.9% of the shares of the stock are short sold.

Auxilium Pharmaceuticals (NASDAQ:AUXL) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.44) earnings per share for the quarter, missing the analysts’ consensus estimate of $1.64 by $2.08. The company had revenue of $83.00 million for the quarter, compared to the consensus estimate of $482.80 million. During the same quarter last year, the company posted $0.22 earnings per share. Auxilium Pharmaceuticals’s revenue was down 17.4% compared to the same quarter last year. On average, analysts predict that Auxilium Pharmaceuticals will post $-0.41 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on AUXL shares. Analysts at RBC Capital cut their price target on shares of Auxilium Pharmaceuticals from $32.00 to $28.00 in a research note on Friday, August 8th. They now have an “outperform” rating on the stock. Separately, analysts at Aegis cut their price target on shares of Auxilium Pharmaceuticals to $34.00 in a research note on Thursday, August 7th. They noted that the move was a valuation call. Finally, analysts at Aegis initiated coverage on shares of Auxilium Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $37.00 price target on the stock.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.